Nemaura Medical Inc (NMRD)

[ProfitScout]

Good to see the official announcement from NMRD today on the company's important opportunity to present its diagnostic products and latest developments to a large, industry targeted audience base coming up next week.

Nemaura Medical to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

Loughborough, England, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the MicroCap Rodeo Windy City Roundup 2022 Conference. The conference is being held on October 12 - 13, 2022 at the Swissotel Chicago.

Presentation Date: October 12, 2022

Time: 1:00 pm CT

Dr. Chowdhury will be available for one-on-one meetings with investors who are registered to attend the conference. To schedule a meeting, please email [e-mail]

To register for the conference, click here: https://microcaprodeo.com/signup

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT(R) to the U.S. FDA. proBEAT(TM) combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R)diabetes program that is currently undergoing pilot studies.

Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one's overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit http://www.NemauraMedical.com.

Contact:

Jules Abraham

CORE IR

917-885-7378

[e-mail]